News & Videos - QUANTERIX CORP.

LOS ANGELES, CA / ACCESSWIRE / November 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Eli Lilly and Company, a global healthcare company, presented new data from Lilly’s Phase 2 TRAILBLAZER-ALZ study at AAIC 2021 utilizing Quanterix’ highly sensitive Simoa® technology. The study utilized Quanterix’ Simoa ® HD-X technology and assays to measure P-tau217 (tau phosphorylated at threonine 217), using antibodies...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2021 after the close of trading on Aug. 5, 2021. Company management will host a conference call at 4:30pm ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix. Individuals interested in...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Simoa® technology has been used in a worldwide collaborative study of the plasma neurofilament light (NfL) biomarker to evaluate its utility for a range of neurological conditions. Published in Nature Communications , the research marks the most robust effort to date assessing the use of NfL in blood to screen for neurodegeneration as...

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 th at 3:50pm ET. Attendees can access the public webcast at https://kvgo.com/gs-global-healthcare/quanterix-june-2021 or by visiting the News & Events page within the Investors...

Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. “We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our...

Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021. “We made productive advances on our strategic and operational priorities during the first quarter 2021,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “The precision health ecosystem continues to catalyze interest and adoption from...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for first quarter 2021 after the close of trading on Wednesday, May 5, 2021. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix. Individuals...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the appointment of Laurie Olson to its Board of Directors, effective April 27, 2021. Olson is a seasoned pharmaceutical executive who brings more than three decades of experience in commercial and corporate strategy from Pfizer, Inc. to the Quanterix Board. She most recently served as executive vice president, strategy and commercial operations...

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a webinar with leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. With several pharmaceutical companies making significant advances towards approval of Alzheimer's Disease therapies, this webinar discussion and live Q and A will further show...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has appointed Shawn Stetson as the Company's interim chief financial officer, effective May 11, 2021. Mr. Stetson will assume his new responsibilities upon the departure of the Company’s current chief financial officer Amol Chaubal, who has accepted the chief financial officer role at Waters Corporation. Quanterix has initiated a...

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa® technology has been used in research studies to detect the SARS-CoV-2 virus in serum/plasma, dried blood microsamples (DBS) and saliva samples obtained from polymerase chain reaction (PCR)+ COVID-19 patients. Published in Nature Communications , the research study of these technologies offers further evidence that non-invasive antigen detection...

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology and various blood-based neurology biomarker assays were used by leading research teams to power 30 total oral and poster presentations at this year’s AD/PD 2021 . The research efforts further underscore the vast utility of several blood-based biomarkers offered through Quanterix’ Neurology kits , including...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2020. “Responding to the pandemic crisis as well as advances in therapies to treat Alzheimer’s has accelerated our leadership of precision health and the proteomics revolution,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “There is a strong...

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be delivering a virtual presentation at the Cowen 41 st Annual Health Care Conference on Wednesday, March 3, at 11:00 a.m. EST. Attendees can access the public webcast at https://wsw.com/webcast/cowen81/qtrx/2002443 or by visiting the News & Events page within the Investors section of...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for fourth quarter and full year 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chairman, Chief Executive Officer and...

Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be presenting at the 10 th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 22 – 26, 2021. Hrusovsky’s presentation will take place on Friday, February 26, at 9:20 a.m. EST. Attendees can access the public webcast at...

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix’ industry leading biomarker testing and development offerings across China and the APAC market. The Simoa® Joint Lab is the strategic partnership between the two companies and will be established at WuXi AppTec’s Shanghai facility. The...

Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts...

Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock at a public offering price of $70.00 per share. All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, are expected to be...